H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating

CG Oncology, Inc. (NASDAQ:CGON) is among the 10 Fastest Growing NASDAQ Stocks to Buy.

On February 27, 2026, H.C. Wainwright raised the firm's price target on CG Oncology, Inc. (NASDAQ:CGON) to $80 from $75 and maintained a Buy rating on the shares. The analyst said the company is advancing toward a biologics application submission for cretostimogene in high-risk non-muscle invasive bladder cancer, supported by strong durability and safety data, while also expanding into earlier treatment settings. The firm added that the Phase 3 PIVOT-006 trial in intermediate-risk NMIBC represents a key 2026 catalyst that could significantly broaden the company’s clinical and commercial opportunity.

On February 27, 2026, CG Oncology, Inc. (NASDAQ:CGON) reported FY25 EPS of ($2.08), compared with consensus estimates of (58c). The company reported revenue of $4.04M, above the $515,180 consensus estimate. Chairman and CEO Arthur Kuan said the company expects to report topline data from PIVOT-006 in the coming months, describing the study as “the first randomized registrational trial to evaluate an investigational therapy in intermediate-risk NMIBC.” Kuan added that the company believes it has the opportunity to establish a new standard in intermediate-risk NMIBC and highlighted cretostimogene’s “unique best-in-disease profile.” He also noted that results from CORE-008 Cohort CX in high-risk BCG-exposed patients evaluating cretostimogene in combination with gemcitabine are expected in the coming quarter.

CG Oncology, Inc. (NASDAQ:CGON) is a late-stage clinical biopharmaceutical company that develops and commercializes bladder-sparing therapeutics for patients with bladder cancer.

While we acknowledge the potential of CGON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026